Detalhe da pesquisa
1.
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
N Engl J Med
; 390(10): 875-888, 2024 Mar 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38446675
2.
An HNF4α-miRNA inflammatory feedback circuit regulates hepatocellular oncogenesis.
Cell
; 147(6): 1233-47, 2011 Dec 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-22153071
3.
Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer.
Curr Issues Mol Biol
; 46(4): 2827-2844, 2024 Mar 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38666907
4.
Gain of Chromosome 5q Predicts a Favorable Prognosis in Localized Renal Cell Carcinoma.
Cancer Invest
; 42(1): 97-103, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38314786
5.
Inhibition of IL-17A Protects against Thyroid Immune-Related Adverse Events while Preserving Checkpoint Inhibitor Antitumor Efficacy.
J Immunol
; 209(4): 696-709, 2022 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35817515
6.
Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920.
Cancer
; 128(5): 966-974, 2022 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34784056
7.
Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer.
BJU Int
; 130(5): 592-603, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34597472
8.
Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy.
Br J Clin Pharmacol
; 88(7): 3182-3192, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35029306
9.
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 22(4): 525-537, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33721560
10.
Pegilodecakin as monotherapy or in combination with anti-PD-1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: Final results of cohorts A, G, H and I of IVY Phase I study.
Int J Cancer
; 149(2): 403-408, 2021 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33709428
11.
Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes.
BJU Int
; 128(2): 196-205, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33556233
12.
VEGF inhibition in urothelial cancer: the past, present and future.
World J Urol
; 39(3): 741-749, 2021 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-32361873
13.
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial.
Lancet Oncol
; 21(1): 105-120, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31753727
14.
Patient-reported outcomes and inflammatory biomarkers in patients with locally advanced/metastatic urothelial carcinoma treated with durvalumab in phase 1/2 dose-escalation study 1108.
Cancer
; 126(2): 432-443, 2020 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31581306
15.
Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors.
Cancer
; 126(6): 1208-1216, 2020 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31829450
16.
Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study.
J Urol
; 204(1): 63-70, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31971495
17.
Evaluation of the prognostic role of co-morbidities on disease outcome in renal cell carcinoma patients.
World J Urol
; 38(6): 1525-1533, 2020 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-31520111
18.
Health-related quality of life in the randomized phase 3 study of ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced urothelial carcinoma (RANGE).
BMC Urol
; 20(1): 181, 2020 Nov 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33160359
19.
Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial.
Lancet Oncol
; 20(11): 1544-1555, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31563517
20.
To treat or not to treat: Patient exclusion in immune oncology clinical trials due to preexisting autoimmune disease.
Cancer
; 125(20): 3506-3513, 2019 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31318445